HER2 Low Expression in Primary Male Breast Cancer
(Source: Vascular Health and Risk Management)
Source: Vascular Health and Risk Management - March 28, 2024 Category: Cardiology Tags: Breast Cancer: Targets and Therapy Source Type: research
Deciphering the causal association and co-disease mechanisms between psoriasis and breast cancer
ConclusionThe results suggest that psoriasis may increase the risk of BC, especially ER- BC, while reverse MR suggests a decreased risk of psoriasis in Her2+ BC. Transcriptome analysis revealed a shared mechanism between psoriasis and BC. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 28, 2024 Category: Allergy & Immunology Source Type: research
HER2-Positive Metastatic Colorectal Cancer
Opinion statementTargeted treatment strategies are available for human epidermal growth factor receptor 2 (HER2) –positive (amplified and/or overexpressed) metastatic colorectal cancer (mCRC), and HER2 testing is indicated in patients with mCRC. At present, standard of care first-line treatment for those with HER2-positive mCRC remains chemotherapy in combination with epidermal growth factor receptor (EGFR) inhibitors or bevacizumab, depending onRAS/BRAF mutational status and tumor sidedness. HER2-targeted agents should be considered for those withRAS/BRAF wild-type disease in subsequent-line treatment and in first-line ...
Source: Current Treatment Options in Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study
ConclusionNeoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Establishment and characterization of multiple patient-derived organoids from a case of advanced endometrial cancer
AbstractPatient-derived organoids (PDOs) retain the original tumor ’s characteristics to a large degree and allow direct evaluation of the drug sensitivity, thereby emerging as a valuable resource for both basic and preclinical researches. Whereas most past studies stereotypically adopted a single PDO as an avatar of the patient, it remains to be investigated whe ther this assumption can be justified even for the tumor with spatial diversity. To address this issue, we established and characterized multiple PDOs originating from various sites of a patient with advanced uterine carcinosarcoma (UCS). Specifically, cancer ce...
Source: Human Cell - March 28, 2024 Category: Cytology Source Type: research
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
ConclusionsIn this systematic review, data from RCTs showed that palbociclib was effective, well tolerated, and maintained QoL in older patients with HR+/HER2 − a/mBC. Palbociclib treatment in older patients in real-world settings was associated with similar clinical benefit as in RCTs.PROSPERO RegistrationCRD42023444195. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies
CONCLUSIONS: Our study proposes smart, novel and safe multifunctional nanoplatforms simultaneously addressing cancer-stroma within the tumor microenvironment, which are: (i) actively delivered to the targeted cells through highly specific aptamers; (ii) localized by means of their luminescence, and (iii) activated via minimally invasive light, launching efficient tumor death, thus providing innovative precision therapeutics. Given the unique features, the proposed dual targeted nanoformulations may open a new door to precision cancer treatment.PMID:38532439 | DOI:10.1186/s13046-024-03014-x (Source: Cell Research)
Source: Cell Research - March 27, 2024 Category: Cytology Authors: Simona Camorani Alessandra Caliendo Elena Morrone Lisa Agnello Matteo Martini Monica Cantile Margherita Cerrone Antonella Zannetti Massimo La Deda Monica Fedele Loredana Ricciardi Laura Cerchia Source Type: research
Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies
CONCLUSIONS: Our study proposes smart, novel and safe multifunctional nanoplatforms simultaneously addressing cancer-stroma within the tumor microenvironment, which are: (i) actively delivered to the targeted cells through highly specific aptamers; (ii) localized by means of their luminescence, and (iii) activated via minimally invasive light, launching efficient tumor death, thus providing innovative precision therapeutics. Given the unique features, the proposed dual targeted nanoformulations may open a new door to precision cancer treatment.PMID:38532439 | DOI:10.1186/s13046-024-03014-x (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Simona Camorani Alessandra Caliendo Elena Morrone Lisa Agnello Matteo Martini Monica Cantile Margherita Cerrone Antonella Zannetti Massimo La Deda Monica Fedele Loredana Ricciardi Laura Cerchia Source Type: research
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
CONCLUSION: Although the acelERA BC study did not reach statistical significance for its primary INV-PFS end point, there was a consistent treatment effect with giredestrant across most key subgroups and a trend toward favorable benefit among patients with ESR1-mutated tumors. Giredestrant was well tolerated, with a safety profile comparable to PCET and consistent with known endocrine therapy risks. Overall, these data support the continued investigation of giredestrant in other studies.PMID:38537155 | DOI:10.1200/JCO.23.01500 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Miguel Mart ín Elgene Lim Mariana Chavez-MacGregor Aditya Bardia Jiong Wu Qingyuan Zhang Zbigniew Nowecki Felipe Melo Cruz Rustem Safin Sung-Bae Kim Christian Schem Alberto J Montero Sarah Khan Reeti Bandyopadhyay Heather M Moore Mahesh Shivhare Monika P Source Type: research
Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers
CONCLUSIONS: sWGS and targeted sequencing identified therapeutic opportunities in 75% of p53abn EC patients. Further research is needed to determine the efficacy of treatments targeting these identified pathways within p53abn ECs.PMID:38536067 | DOI:10.1158/1078-0432.CCR-23-3689 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 27, 2024 Category: Cancer & Oncology Authors: Amy Jamieson Juliana Sobral de Barros Dawn R Cochrane J Maxwell Douglas Sameer Shankar Branden J Lynch Samuel Leung Spencer Martin Janine Senz Amy Lum Yvette Drew C Blake Gilks David G Huntsman Jessica N McAlpine Source Type: research
Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study
Curr Oncol. 2024 Feb 27;31(3):1278-1290. doi: 10.3390/curroncol31030096.ABSTRACTFor early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a need to identify patients who de-rive the most benefit from molecular assays and where this test may be of poor value. In this multicenter prospective cohort study, we evaluated whether use of PREDICT 2.1 would impact physician decision making. For the first 6 months of the study, data on physician...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Arif Ali Awan Deanna Saunders Gregory Pond Caroline Hamm Nadia Califaretti Mihaela Mates Vikaash Kumar Mohammed F K Ibrahim Ana-Alicia Beltran-Bless Lisa Vandermeer John Hilton Mark Clemons Source Type: research
Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland
Conclusions: The use of this test resulted in a 75% reduction in chemotherapy and a significant cost savings in our publicly funded health system.PMID:38534931 | DOI:10.3390/curroncol31030098 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Lynda M McSorley Mehala Tharmabala Fathiya Al Rahbi Fergus Keane Denis Evoy James G Geraghty Jane Rothwell Damian P McCartan Megan Greally Miriam O'Connor Deirdre O'Mahony Maccon Keane Michael John Kennedy Seamus O'Reilly Steve J Millen John P Crown Cathe Source Type: research
